Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;16(2):412-418.
doi: 10.1080/21645515.2019.1650999. Epub 2019 Sep 5.

Immunological considerations in the development of Pseudomonas aeruginosa vaccines

Sarah M Baker  1 , James B McLachlan  1 , Lisa A Morici  1
Affiliations
Review

Immunological considerations in the development of Pseudomonas aeruginosa vaccines

Sarah M Baker et al. Hum Vaccin Immunother. 2020.

Abstract

Pseudomonas aeruginosa is an opportunistic human pathogen capable of causing a wide range of potentially life-threatening infections. With multidrug-resistant P. aeruginosa infections on the rise, the need for a rationally-designed vaccine against this pathogen is critical. A number of vaccine platforms have shown promising results in pre-clinical studies, but no vaccine has successfully advanced to licensure. Growing evidence suggests that an effective P. aeruginosa vaccine may require Th17-type CD4+ T cells to prevent infection. In this review, we summarize recent pre-clinical studies of P. aeruginosa vaccines, specifically focusing on those that induce Th17-type cellular immunity. We also highlight the importance of adjuvant selection and immunization route in vaccine design in order to target vaccine-induced immunity to infected tissues. Advances in cellular immunology and adjuvant biology may ultimately influence better P. aeruginosa vaccine platforms that can protect targeted human populations.

Keywords: Pseudomonas aeruginosa; Th17; cellular immunity; vaccines.

PubMed Disclaimer

References

    1. World Health Organization . Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva (Switzerland): WHO; 2017.
    1. Klockgether J, Cramer N, Wiehlmann L, Davenport CF, Tümmler B.. Pseudomonas aeruginosa genomic structure and diversity. Front Microbiol. 2011;2:150. doi:10.3389/fmicb.2011.00215. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States; 2013.
    1. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol. 2001;183:5395–401. doi:10.1128/JB.183.18.5395-5401.2001. - DOI - PMC - PubMed
    1. Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 2008;26:1011–24. doi:10.1016/j.vaccine.2007.12.007. - DOI - PubMed